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The demand for fast dissolving tablets has been growing during the last decade, especially for elderly 
and children who have swallowing difficulties. In the present work, fast dissolving tablets of metoprolol 
tartrate, were prepared using sodium starch glycolate, sodium croscarmellose and crospovidone as 
superdisintegrants, by the direct compression method. The tablets prepared were evaluated for various 
parameters including weight variation, hardness, friability, in vitro dispersion time, drug-polymer 
interaction, drug content water absorption ratio, wetting time, in vitro drug release, FTIR and DSC 
studies. The tablets prepared by the direct compression method had a weight variation in the range of 
145 mg to 152 mg, which is below ± 7.5%, a hardness of 3.6 kg/cm2 to 4.5 kg/cm², percentage friability 
of 0.46% to 0.73%, in vitro dispersion time of 18 s to 125 s, drug content uniformity of between 98.12% 
and 100.03%, a water absorption ratio of 67% to 87%, wetting time of 32 sec. to 64 sec., and an in vitro 
drug release of 53.92% - 98.82% within 15 min. The IR spectral analysis and DSC study showed no 
drug interaction with formulation additives of the tablet, and the formulations indicated no significant 
changes in hardness, friability, drug content or in vitro drug release. Fast dissolving tablets of metoprolol 
tartrate have enhanced dissolution and will lead to improved bioavailability and more effective therapy.
Uniterms: Fast dissolving tablets/in vitro evaluation. Fast dissolving tablets/formulation. Metoprolol 
tartrate/fast dissolving tablets/formulation. Metoprolol tartrate/in vitro evaluation. Sodium croscarmellose. 
Sodium starch glycolate. Crospovidone. In vitro dispersion time/tablets evaluation.
A exigência por comprimidos de dissolução rápida aumentou durante a última década, especialmente 
para idosos e crianças, com dificuldades de deglutição . No presente trabalho prepararam-se, pelo 
método de compressão direta, comprimidos de tartarato de metoprolol de rápida dissolução, utilizando 
glicolato sódico de amido, croscarmellose sódica e crospovidona como superdisintegrantes. Os 
comprimidos preparados foram avaliados em relação a diferentes parâmetros, como variação de peso, 
dureza, friabilidade, tempo de dispersão in vitro, interação fármaco-polímero, taxa de absorção de água 
pelo fármaco, tempo de umedecimento, liberação do fármaco in vitro,, FTIR e estudos de DSC. Os 
comprimidos preparados por compressão direta apresentaram variação de peso de 145 mg a 152 mg, 
abaixo de ±7,5%, dureza de 3,6 kg/cm² a 4,5 kg/cm² , porcentagem de friabilidade de 0,46% a 0,73%, 
tempo de dispersão in vitro de 18 s a 125 s, uniformidade de conteúdo de fármaco entre 98,12% e 
100,03%, taxa de absorção de água de 67% a 87%, tempo de umidificaçãode 32 s a 64 s liberação do 
fármaco in vitro entre 53,92% e 98,82%, em 15 min. A análise no IV e de DSC mostrou que não houve 
interação de fármacos com os aditivos de formulação do comprimido e as formulações indicaram que 
não houve mudança significativa na dureza, friabilidade, s uniformidade de conteúdo de fármaco e na 
liberação do fármaco in vitro. Os comprimidos de liberação rápida apresentaram aumento na dissolução 
de tartarato metoprolol e conduzem à melhoria dabiodisponibilidade e à terapia eficaz. 
Unitermos: Comprimidos de dissolução rápida/avaliação in vitro. Comprimidos de dissolução rápida/
formulação. Tartarato de metoprolol/comprimidos de dissolução rápida/formulação. Tartarato de 
metoprolol/ avaliação in vitro. Croscarmelose sódica. Glicolato sódico de amido. Crospovidone. Tempo 
de dispersão in vitro/avaliação de comprimidos.
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INTRODUCTION
Elderly people, children and patients sometimes 
have difficulties swallowing tablets or hard gelatin 
capsules. In addition, such difficulties apply not only 
to patients but also to active working people who have 
no access to water. These problems can be resolved by 
means of tablets which disintegrate rapidly in the mouth 
(Sugimoto et al., 2006).
Recently, fast dissolving tablets (FDTs) have 
become increasingly popular around the world. On the 
basis of requests from patients to enhance their quality 
of life (QOL), new types of FDTs have been developed 
and then released globally by many pharmaceutical 
companies (Okuda et al., 2011). These tablets display a 
fast and spontaneous de-aggregation in the mouth, soon 
after coming into contact with saliva, dissolving the active 
ingredient and allowing absorption through all possible 
membranes it comes into contact with during deglutition 
(Puttewar et al., 2010).
Fast dissolving tablets are useful for patients with 
difficulties swallowing conventional tablets, for example 
pediatric patients and patients under chemotherapy 
treatment. Patients on chemotherapy treatment may 
have nausea which is so intense that it complicates the 
administration of conventional tablets; typically this has 
been done with water, especially in those with tumors of 
the mouth and esophagus. Nausea and emesis continue 
to cause significant problems for patients with cancer 
receiving highly or moderately emetogenic chemotherapy 
(Armando et al., 2009). Direct absorption through the 
oral mucosa allows drugs to achieve systemic circulation, 
bypassing the gastrointestinal tract and the first-pass 
metabolism of the liver. To allow fast dissolving of dosage 
forms in the mouth, these delivery systems comprise either 
very porous and soft-moulded matrices or compression 
into tablets with very low compression force (Lai et al., 
2011).
However, as a result of rapid FDT disintegration, the 
active substance comes into contact with the taste buds 
and the need for a pleasant taste becomes a key aspect 
for patient palatability. Thus, the taste-masking of bitter 
active substances is a critical hurdle to overcome for the 
successful development of FDT formulations. In general, 
oral administration of bitter active substances through 
FDT formulations should provide an improved degree 
of palatability and increased patient compliance with 
dissolving/disintegrating tablets that include sweeteners 
and flavors. Nevertheless, these additives were not a 
sufficient means for complete taste-masking. Recent 
advances in technology have presented viable dosage 
alternatives to taste-mask bitter drugs. Several approaches 
have been reported which involve complexation, freeze-
drying, microencapsulation, fluidized-bed coating and 
supercritical fluids for taste-masking purposes (Gryczkc 
et al., 2011).
MATERIAL AND METHODS
Metoprolol tartrate was obtained from Cipla 
Pharma, Mumbai, India. Crospovidone, sodium starch 
glycolate and sodium croscarmellose were also obtained 
from Cipla Pharma Mumbai, India. Microcrystalline 
cellulose and mannitol were obtained from Ajantha 
Pharma, Aurangabad. All other chemicals of analytical 
grade were purchased from commercial sources.
Preparation of fast dissolving tablets by direct 
compression method
Fast dissolving tablets of metoprolol tartrate were 
prepared by direct compression. All the ingredients (except 
granular directly compressible excipients) were passed 
through # 60-mesh separately. The ingredients were then 
weighed and mixed in geometrical order and compressed 
into tablets of 150 mg using 6 mm round concave punches 
on an 8-station rotary tablet machine (Karnavati) (Shirsand 
et al., 2010) (Table I).
Evaluation of metoprolol tartrate fast dissolving 
tablets
Evaluation of pre-compression parameters of powder
·	 Preformulation study
·	 Angle of repose (q)
The angle of repose was determined by using the 
funnel method. The accurately weighed blend was taken 
in a funnel. The height of the funnel was adjusted in such a 
way that the tip of funnel just touched the apex of the heap 
and the drug-excipient blend was allowed to flow through 
the funnel freely to the surface. The diameter of the powder 
cone was measured and angle of repose calculated using 
the following equation.
Tan θ = h/r
Different ranges of flowability in terms of angle 
of repose (Table II) are given below (Bikshapathi et al., 
2011).
·	 Bulk density (Pb)
Apparent bulk density (Pb) was determined by 
pouring the blend into a graduated cylinder. The bulk 
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TABLE I - Formulation of metoprolol tartrate fast dissolving tablets prepared by direct compression method
Ingredient(mg)
Formulation code
MT1 MT2 MT3 MT4 MT5 MT6 MT7 MT8 MT9
Metoprolol tartrate 25 25 25 25 25 25 25 25 25
Sodium croscarmellose 05 10 15
Crospovidone 05 10 15
Sodium starch glycolate 5 10 15
Aspartame 10 10 10 10 10 10 10 10 10
Mg stearate 02 02 02 02 02 02 02 02 02
Aerosil 03 03 03 03 03 03 03 03 03
Methyl cellulose 03 03 03 03 03 03 03 03 03
MCC(Avicel PH-102) 37 37 37 37 37 37 37 37 37
D- Mannitol 65 60 55 65 60 55 65 60 55
Total 150 150 150 150 150 150 150 150 150
Formulation code: MT1 - Formulation containing 3.3% sodium croscarmellose; MT 2 - Formulation containing 6.6% sodium 
croscarmellose; MT 3 - Formulation containing 10% sodium croscarmellose; MT 4 - Formulation containing 3.3% crospovidone; 
MT 5 - Formulation containing 6.6% crospovidone; MT 6 - Formulation containing 10% crospovidone; MT 7 - Formulation 
containing 3.3% sodium starch glycolate; MT 8 - Formulation containing 6.6% sodium starch glycolate; MT 9 - Formulation 
containing 10% sodium starch glycolate.
TABLE II - Relationship between angle of repose (q) and flow 
properties





volume (Vb) and weight of powder (M) was determined. 
The bulk density was calculated using the formula (ShahV 
et al., 2011).
Pb = M/Vb
·	 Tapped density (Pt)
The measuring cylinder containing a known mass 
of blend was tapped for a fixed time. The minimum 
volume (Vt) occupied in the cylinder and the weight (M) 
of the blend was measured. The tapped density (pt) was 
calculated using the formula (Suresh et al., 2011).
Pt = M/Vt
·	 Hausner’s ratio
Hausners’s ratio is the ratio of tapped density to bulk 
density. The lower the value of Hausner’s ratio the better 
the flow property. The ratio is calculated by the following 
formula
Lower Hausner ratios (<1.25) indicate better flow 
properties than higher ratios (>1.25) (Sayeed et al., 
2011).
·	 Carr’s compressibility index
The percentage compressibility (Carr’s index) was 
calculated as 100 times the ratio of the difference between 
tapped density and bulk density to tapped density (Sayeed 
et al., 2011). (Table III).
It is expressed in percentage and calculated by the 
following formula
TABLE III - Grading of the powders for their flow properties 
according to Carr’s index
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Drug polymer interaction studies
·	 FTIR study
The study was carried out to determine the 
molecular structure, serving as an identification test to 
ascertain the purity of the molecule. IR spectroscopy was 
obtained by a FTIR spectrophotometer (H400-84100, 
Shimadzu, Japan) using KBr pellets. The scanning range 
used was 4400 to 400 cm-1 at a scan period of 1min. 
Spectra of pure drug and the blend are shown in Figures 1 
and 2. There is no change in the shape of the peak or shift 
of the peak, hence the drug and excipients are compatible 
( Prameela et al., 2010).
·	 Differential scanning calorimetry (DSC) Study
DSC analysis of pure drug, and of the optimized 
formulation was performed on a Shimadzu DSC 60 
thermal analyser at the heating flow rates of 5 °C per min 
between 50-300 °C under static air using aluminium pans 
(Nayak et al., 2011).
Evaluation of post-compression parameters of tablets
·	 Hardness test
The hardness of a tablet is indicative of its tensile 
strength and is measured in terms of load/pressure 
required to crush it when placed on its edge. A number 
of handy hardness testers such as the Mosanto type or 
Pfizer type are currently in use. Hardness of about 5 
kg is considered to be a minimum for uncoated tablets 
for mechanical stability. The hardness is a function 
of physical properties of granules such as hardness 
and deformation under load, binders and above all the 
compressional force. The hardness has an influence on 
disintegration and dissolution times and is, as such, a 
factor that may affect bioavailabilities (Puttewar et al., 
2010).
·	 Friability test
Friability of the tablets was determined using a 
Roche friabilator. This device subjects the tablets to 
the combined effect of abrasions and shock in a plastic 
chamber revolving at 25 rpm, dropping the tablets from 
a height of 6 inches on each revolution. A preweighed 
sample of tablets was placed in the friabilator and 
subjected to 100 revolutions. Tablets were de-dusted using 
a soft muslin cloth and reweighed.
The friability (F%) is given by the formula
Where, W0 is weight of the tablets before the test 
and W is the weight of the tablets after the test (Mehta et 
al., 2009).
·	 Weight variation test
Twenty tablets were selected randomly and average 
weight was determined. Subsequently, individual tablets 
were weighed and compared with average weight. 
If the comparison variation lies within the I.P limits, 
it passes the weight variation test (Chandira et al., 
2010).
·	 Water absorption
A piece of tissue paper folded twice was placed in 
FIGURE 1 - FT-IR spectrum of metoprolol tartrate.
FIGURE 2 - FT-IR spectrum of metoprolol tartrate with sodium 
croscarmellose.
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a small Petri dish containing 6 ml of water. A tablet was 
placed on the paper and the time required for complete 
wetting was measured. The wetted tablet was then 
weighed. Water absorption ratio is indicated by R, which 
is calculated by using the equation below (Chandira et 
al., 2010).
·	 Uniformity of thickness
Thickness can be measured using a simple procedure. 
A total of 5 tablets were taken and their thicknesses 
measured using Vernier calipers. The thickness was 
measured by placing the tablet between the two arms of 
the Vernier calipers (Parmar et al., 2009). 
·	 Drug content uniformity
The formulated tablets were also analyzed for the 
drug uniformity contents as per the Indian Pharmacopoeia. 
A total of 20 tablets were taken, weighed and ground. An 
amount of this powder equivalent to 5 mg of the drug was 
accurately weighed, suitably diluted and analyzed on a 
double-beam UV spectrophotometer (Jasco- 630V) at 
221.70 nm. (Bagul et al., 2010).
·	 Wetting time
A piece of double-folded tissue paper was placed 
in a petri plate (internal diameter 6.5 cm) containing 
6ml of water. The tablet was placed on the paper and the 
time for complete wetting of the tablet was measured 
in seconds. The method was slightly modified by 
maintaining water at 37 οC (Figure 3) (Margret et al., 
2010).
·	 In vitro disintegration time
The disintegration time was measured using 
disintegration test apparatus. One tablet was placed in 
each tube of the basket. This basket was immersed in a 
water bath at 37+ 20 oC. The time required for complete 
disintegration was recorded with standard deviation 
(Chacko et al., 2010) (Table VI)
·	 In vitro dissolution studies
The in vitro dissolution study was performed using 
an USP dissolution apparatus Type 2 (Paddle type) at 
100 rpm using 900 ml phosphate buffer pH 6.8 as the 
dissolution medium at 37±0.5 ºC. Aliquots of dissolution 
medium were withdrawn and the absorbances of filtered 
solutions determined by a UV Spectrophotometer at 
221.70 nm. Six trials were performed for each batch and 
average percentage drug release with standard deviation 
was calculated and recorded (Chacko et al., 2010).
RESULTS AND DISCUSSION
Fast dissolving tablets of metoprolol tartrate 
were prepared by a method employing crospovidone, 
sodium starch glycolate and sodium croscarmellose as 
super-disintegrants at different ratios. A total of nine 
formulations were designed. The flow properties of 
the powder mixture are important for the uniformity of 
mass of the tablets; the flow of the powder mixture was 
analyzed before compression to tablets. Low Hausner`s 
ratio (≤1.14), compressibility index (≤15) and angle of 
repose (≤ 28.04) values indicated fairly good flowability 
of the powder mixture (Table IV).
As the tablet powder mixture was free flowing, 
tablets produced were of uniform weight with acceptable 
weight variation in the range from 145 mg to 152 mg due 
to uniform die fill. Hardness (3.6 kg/cm2- 4.5 kg/cm2) and 
friability loss (0.46% - 0.73%) indicated that tablets had 
good mechanical resistance. Drug content was found to 
be high (≥ 98.12 %) in all the tablet formulations. Water 
absorption ratio and wetting time, which are important 
criteria for understanding the capacity of disintegrants 
to swell in the presence of a small amount of water, were 
FIGURE 3 – Wetting time determination.
M. M. Satpute, N. S. Tour788
found to be in the range of 67.32% - 87.91% and 28 sec - 
57 sec, respectively (Tables V and VI). 
The most important parameter that needs to be 
optimized in the development of fast disintegrating 
tablets is the disintegration time of tablets. In the 
present study, it was observed that the disintegration 
time of the tablets had no effect with increasing level of 
TABLE IV - Pre-compression results of direct compression method









MT1 0.54 0.65 28.04 16 1.20
MT2 0.52 0.63 30.14 17 1.21
MT3 0.51 0.62 28.85 17 1.21
MT4 0.55 0.65 28.26 15 1.14
MT5 0.50 0.63 28.43 20 1.26 
MT6 0.53 0.64 30.01 17 1.20
MT7 0.53 0.63 30.02 15 1.20
MT8 0.51 0.62 28.87 17 1.21
MT9 0.52 0.65 27.52 18 1.21
Formulation code: MT 1 - Formulation containing 3.3% sodium sodium croscarmellose; MT 2 - Formulation containing 6.6% sodium 
sodium croscarmellose; MT 3 - Formulation containing 10% sodium croscarmellose croscarmellose; MT 4 - Formulation containing 
3.3% crospovidone; MT 5 - Formulation containing 6.6% crospovidone; MT 6 - Formulation containing 10% crospovidone; MT 
7 - Formulation containing 3.3% sodium starch glycolate; MT 8 - Formulation containing 6.6% sodium starch glycolate; MT 9 - 
Formulation containing 10% sodium starch glycolate.
crospovidone. The faster disintegration of crospovidone 
tablets may be attributed to its rapid capillary activity 
and pronounced hydration with low capacity for gel 
formation. Thus, these results suggest that disintegration 
times can be reduced by using a wicking type disintegrant 
(crospovidone). Thus, wetting times of tablets with 
crospovidone were found to be less than those with 
TABLE V - Post-compressional parameters for direct compression method
Formulation Code Hardness* (kg/cm²) Mean ± SD Friability (%)
Thickness* (mm) 
Mean ± SD
Weight variation (mg) 
Mean ± SD
MT1 4.3 ± 0.11 0.46 4.3 ±0.05 146 ± 1.37
MT2 3.7 ± 0.15 0.66 4.2 ±0.07 145 ± 1.35
MT3 3.5 ± 0.15 0.70 4.6 ±0.10 149 ± 1.40
MT4 4.3 ± 0.19 0.60 4.4 ±0.09 148 ± 1.34
MT5 4.1 ± 0.14 0.46 4.1 ±0.20 149 ± 1.31
MT6 4.4 ± 0.23 0.56 4.6 ± 0.10 148 ± 1.40
MT7 4.5 ± 0.07 0.73 4.8 ± 0.10 150 ± 1.24
MT8 4.2 ± 0.10 0.53 4.5 ± 0.11 152 ± 1.35
MT9 3.6 ± 0.19 0.66 4.6 ± 0.05 147 ± 1.36
Values expressed as Mean ± SD (n=3).
Formulation code: MT 1 - Formulation containing 3.3% sodium sodium croscarmellose; MT 2 - Formulation containing 6.6% sodium 
croscarmellose roscarmellose; MT 3 - Formulation containing 10% sodium sodium croscarmellose; MT 4 - Formulation containing 
3.3% crospovidone; MT 5 - Formulation containing 6.6% crospovidone; MT 6 - Formulation containing 10% crospovidone; MT 
7 - Formulation containing 3.3% sodium starch glycolate; MT 8 - Formulation containing 6.6% sodium starch glycolate; MT 9 - 
Formulation containing 10% sodium starch glycolate.
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TABLE VI - Post-compressional parameters for direct compression method
Formulation Code In vitro dispersion time* (sec) Wetting time
* (sec) Water absorption ratio* Drug Content* (%)
MT1 35 ± 1.27 49 ± 1.36 84 ± 1.05 99.18 ± 0.72
MT2 92 ± 1.25 46 ± 1.18 74± 0.80 99.81 ± 1.07
MT3 62 ± 1.30 42 ± 1.22 67 ± 1.06 99.54 ± 0.50
MT4 22 ± 1.37 32 ± 1.29 82 ± 1.28 98.12 ± 0.73
MT5 18 ± 1.35 28 ± 1.27 87 ± 1.36 99.30 ± 0.87
MT6 25 ± 1.36 36 ± 1.37 81 ± 1.38 99.23 ± 0.90
MT7 99 ± 1.31 57 ± 1.32 71 ± 1.34 100.03 ± 1.07
MT8 116 ± 1.35 64 ± 1.36 75 ± 1.44 99.63 ± 0.39
MT9 125 ± 1.40 48 ± 1.40 74± 1.31 99.50 ± 0.77
Values expressed as Mean ± SD (n=3).
Formulation code: MT 1 - Formulation containing 3.3% sodium sodium croscarmellose; MT 2 - Formulation containing 6.6% 
sodium sodium croscarmellose; MT 3 - Formulation containing 10% sodium sodium croscarmellose; MT 4 - Formulation containing 
3.3% crospovidone; MT 5 - Formulation containing 6.6% crospovidone; MT 6 - Formulation containing 10% crospovidone; MT 
7 - Formulation containing 3.3% sodium starch glycolate; MT 8 - Formulation containing 6.6% sodium starch glycolate; MT 9 - 
Formulation containing 10% sodium starch glycolate.
sodium starch glycolate or sodium croscarmellose. These 
results are consistent with disintegration test results. IR 
shows the drug interaction study, indicating that the drug 
is compatible with all the excipients (Figures 4 and 5).
The DSC shows that when the drug metoprolol 
tartrate was taken to study its properties at higher 
temperature, it exhibited a melting peak at 126.69 oC with 
very little variation compared with the literature-reported 
temperature. This is probably due to error in experimental 
determination. The DSC of the optimized formulation 
showed a melting peak at 120.19 oC. DSC studies of 
all formulations indicated that no chemical constituent 
produced any reaction products (Figure 6 and 7).
In vitro drug release studies were carried out in 
phosphate buffer pH 6.8 and the dissolution profile 
is depicted in Table VII and Figures 8 - 10. The drug 
release from the optimized batch (MT5) was 98.82% at 
15 min.
FIGURE 4 – FT-IR spectrum of metoprolol tartrate with sodium 
starch glycolate.
FIGURE 5 - FT-IR spectrum of metoprolol tartrate with 
optimized FDT formulation.
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FIGURE 6 – DSC analysis of metoprolol tartrate. FIGURE 7 - DSC analysis of metoprolol tartrate with optimized 
FDT formulation.
TABLE VII - Dissolution of metoprolol tartrate in phosphate buffer pH 6.8 from tablets of MT1 to MT9
Time (min) 
Cumulative % Drug release 
MT1 MT2 MT3 MT4 MT5 MT6 MT7 MT8 MT9
00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
03 50.61 52.34 49.35 52.25 53.92 51.10 47.63 49.35 45.48 
06 64.18 65.35 63.40 66.49 68.78 64.92 59.95 62.45 58.56 
09 75.64 76.80 75.90 77.95 79.10 75.98 69.96 72.30 68.89 
12 88.54 89.72 87.45 92.68 93.90 90.10 75.25 78.23 73.98 
15 93.73 94.20 91.10 97.97 98.82 95.52 82.76 84.88 80.54 
18 96.51 98.45 95.28 88.34 89.56 87.18 
21 93.06 94.12 92.18 
24 97.24 98.41 95.13 
Formulation code: MT 1 - Formulation containing 3.3% sodium croscarmellose; MT 2 - Formulation containing 6.6% sodium 
sodium croscarmellose; MT 3 - Formulation containing 10% sodium sodium croscarmellose; MT 4 - Formulation containing 
3.3% crospovidone; MT 5 - Formulation containing 6.6% crospovidone; MT 6 - Formulation containing 10% crospovidone; MT 
7 - Formulation containing 3.3% sodium starch glycolate; MT 8 - Formulation containing 6.6% sodium starch glycolate; MT 9 - 
Formulation containing 10% sodium starch glycolate.
FIGURE 8 - In vitro release of metoprolol tartrate from tablets 
of MT1 to MT3.
FIGURE 9 - In vitro release of metoprolol tartrate from tablets 
of MT4 to MT6.
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CONCLUSION
In the present work, fast dissolving tablets of 
metoprolol tartrate were prepared by direct compression 
methods using superdisintegrants such as sodium starch 
glycolate, sodium croscarmellose and crospovidone. All 
the tablets of metoprolol tartrate were subjected to tests for 
weight variation, hardness, friability, in vitro dispersion, 
drug polymer interaction, drug content uniformity, water 
absorption ratio, wetting time, and in vitro drug release.
Based on the above studies,  the following 
conclusions can be drawn:
·	 Tablets prepared by direct compression methods 
were found to be good and free from chipping and 
capping. 
·	 The low values of the standard deviation of average 
weight of the prepared tablets indicated weight uni-
formity within the batches prepared.
·	 The hardness of the prepared tablets was found to 
be in the range of 3.6 kg/cm2 to 4.5 kg/cm². The 
friability values of the prepared tablets were found 
to be less than 1%.
·	 IR spectroscopic and DSC studies indicated that the 
drug is compatible with all the excipients.
·	 The in vitro dispersion time of metoprolol tartrate 
prepared by the direct compression method was 
found to be in the range of 18 sec. to 125 sec. ful-
filling the official requirements.
·	 Based on the in vitro disintegration time, formulation 
MT5 (6.6% crospovidone) was found to be promi-
sing and showed a dispersion time of 18 sec and 
wetting time of 28 sec., facilitating faster dispersion 
in the mouth.
·	 The formulation MT5 displayed a good water ab-
sorption ratio of 87.91%, indicating better and faster 
swelling ability of the disintegrants in the presence 
of a small amount of water.
FIGURE 10 - In vitro release of metoprolol tartrate from tablets 
of MT7 to MT9.
·	 The drug content of tablets was uniform across all 
batches, ranging from 98.12% to 100.03%.
·	  The drug release from the optimized batch (MT5) 
was about 98.82% at 15 min.
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